In a review, authors worked to summarize studies that have been completed in animal model experiments and clinical studies that are concentrated on genetic variations and their impact on the incidence of tardive dyskinesia (TD). The authors note that, in addition to the importance of drug- and dose-related factors in the development of TD, individual susceptibility and genetic predisposition are also crucial components to consider. Through their review, eight genes were recognized from preclinical findings that achieved considerable significance in one study or more.

Reference: Tsermpini EE, Redenšek S, Dolžan V. Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies. Front Pharmacol. 2022;12:834129. doi:10.3389/fphar.2021.834129